834 related articles for article (PubMed ID: 24092345)
21. The safety and effectiveness of riociguat to treat chronic thromboembolic pulmonary hypertension.
DeSouza SA; Preston IR
Expert Rev Cardiovasc Ther; 2015 May; 13(5):467-76. PubMed ID: 25797801
[TBL] [Abstract][Full Text] [Related]
22. Rationale and study design of RESPITE: An open-label, phase 3b study of riociguat in patients with pulmonary arterial hypertension who demonstrate an insufficient response to treatment with phosphodiesterase-5 inhibitors.
Hoeper MM; Klinger JR; Benza RL; Simonneau G; Langleben D; Naeije R; Corris PA
Respir Med; 2017 Jan; 122 Suppl 1():S18-S22. PubMed ID: 27887774
[TBL] [Abstract][Full Text] [Related]
23. Discovery and development of sGC stimulators for the treatment of pulmonary hypertension and rare diseases.
Sandner P; Becker-Pelster EM; Stasch JP
Nitric Oxide; 2018 Jul; 77():88-95. PubMed ID: 29738821
[TBL] [Abstract][Full Text] [Related]
24. Renal effects of soluble guanylate cyclase stimulators and activators: a review of the preclinical evidence.
Stasch JP; Schlossmann J; Hocher B
Curr Opin Pharmacol; 2015 Apr; 21():95-104. PubMed ID: 25645316
[TBL] [Abstract][Full Text] [Related]
25. Animal models related to congenital heart disease and clinical research in pulmonary hypertension.
Loukanov T; Geiger R; Agrawal R
Cardiology; 2010; 116(1):18-25. PubMed ID: 20424448
[TBL] [Abstract][Full Text] [Related]
26. Nitric Oxide-Independent Soluble Guanylate Cyclase Activation Improves Vascular Function and Cardiac Remodeling in Sickle Cell Disease.
Potoka KP; Wood KC; Baust JJ; Bueno M; Hahn SA; Vanderpool RR; Bachman T; Mallampalli GM; Osei-Hwedieh DO; Schrott V; Sun B; Bullock GC; Becker-Pelster EM; Wittwer M; Stampfuss J; Mathar I; Stasch JP; Truebel H; Sandner P; Mora AL; Straub AC; Gladwin MT
Am J Respir Cell Mol Biol; 2018 May; 58(5):636-647. PubMed ID: 29268036
[TBL] [Abstract][Full Text] [Related]
27. Soluble Guanylyl Cyclase Activators-Promising Therapeutic Option in the Pharmacotherapy of Heart Failure and Pulmonary Hypertension.
Grześk G; Witczyńska A; Węglarz M; Wołowiec Ł; Nowaczyk J; Grześk E; Nowaczyk A
Molecules; 2023 Jan; 28(2):. PubMed ID: 36677920
[TBL] [Abstract][Full Text] [Related]
28. Riociguat for the treatment of pulmonary hypertension.
Meis T; Behr J
Expert Opin Pharmacother; 2014 Nov; 15(16):2419-27. PubMed ID: 25260791
[TBL] [Abstract][Full Text] [Related]
29. Therapeutic augmentation of NO-sGC-cGMP signalling: lessons learned from pulmonary arterial hypertension and heart failure.
Triposkiadis F; Xanthopoulos A; Skoularigis J; Starling RC
Heart Fail Rev; 2022 Nov; 27(6):1991-2003. PubMed ID: 35437713
[TBL] [Abstract][Full Text] [Related]
30. Nitric oxide-independent stimulation of soluble guanylate cyclase reduces organ damage in experimental low-renin and high-renin models.
Sharkovska Y; Kalk P; Lawrenz B; Godes M; Hoffmann LS; Wellkisch K; Geschka S; Relle K; Hocher B; Stasch JP
J Hypertens; 2010 Aug; 28(8):1666-75. PubMed ID: 20613628
[TBL] [Abstract][Full Text] [Related]
31. Riociguat: a novel therapeutic option for pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension.
Mielniczuk LM; Swiston JR; Mehta S
Can J Cardiol; 2014 Oct; 30(10):1233-40. PubMed ID: 25154043
[TBL] [Abstract][Full Text] [Related]
32. Soluble Guanylate Cyclase Stimulators and Activators.
Sandner P; Zimmer DP; Milne GT; Follmann M; Hobbs A; Stasch JP
Handb Exp Pharmacol; 2021; 264():355-394. PubMed ID: 30689085
[TBL] [Abstract][Full Text] [Related]
33. Riociguat: first global approval.
Conole D; Scott LJ
Drugs; 2013 Nov; 73(17):1967-75. PubMed ID: 24218053
[TBL] [Abstract][Full Text] [Related]
34. From molecules to patients: exploring the therapeutic role of soluble guanylate cyclase stimulators.
Sandner P
Biol Chem; 2018 Jun; 399(7):679-690. PubMed ID: 29604206
[TBL] [Abstract][Full Text] [Related]
35. Stimulation of the soluble guanylate cyclase (sGC) inhibits fibrosis by blocking non-canonical TGFβ signalling.
Beyer C; Zenzmaier C; Palumbo-Zerr K; Mancuso R; Distler A; Dees C; Zerr P; Huang J; Maier C; Pachowsky ML; Friebe A; Sandner P; Distler O; Schett G; Berger P; Distler JH
Ann Rheum Dis; 2015 Jul; 74(7):1408-16. PubMed ID: 24567525
[TBL] [Abstract][Full Text] [Related]
36. Soluble guanylate cyclase activator reverses acute pulmonary hypertension and augments the pulmonary vasodilator response to inhaled nitric oxide in awake lambs.
Evgenov OV; Ichinose F; Evgenov NV; Gnoth MJ; Falkowski GE; Chang Y; Bloch KD; Zapol WM
Circulation; 2004 Oct; 110(15):2253-9. PubMed ID: 15466650
[TBL] [Abstract][Full Text] [Related]
37. Guanylate cyclase stimulators for pulmonary hypertension.
Wardle AJ; Seager MJ; Wardle R; Tulloh RM; Gibbs JS
Cochrane Database Syst Rev; 2016 Aug; 2016(8):CD011205. PubMed ID: 27482837
[TBL] [Abstract][Full Text] [Related]
38. A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of the Efficacy and Safety of the Oral Soluble Guanylate Cyclase Stimulator: The VICTORIA Trial.
Armstrong PW; Roessig L; Patel MJ; Anstrom KJ; Butler J; Voors AA; Lam CSP; Ponikowski P; Temple T; Pieske B; Ezekowitz J; Hernandez AF; Koglin J; O'Connor CM
JACC Heart Fail; 2018 Feb; 6(2):96-104. PubMed ID: 29032136
[TBL] [Abstract][Full Text] [Related]
39. Stimulation of soluble guanylate cyclase reduces experimental dermal fibrosis.
Beyer C; Reich N; Schindler SC; Akhmetshina A; Dees C; Tomcik M; Hirth-Dietrich C; von Degenfeld G; Sandner P; Distler O; Schett G; Distler JH
Ann Rheum Dis; 2012 Jun; 71(6):1019-26. PubMed ID: 22294631
[TBL] [Abstract][Full Text] [Related]
40. The chemistry and biology of soluble guanylate cyclase stimulators and activators.
Follmann M; Griebenow N; Hahn MG; Hartung I; Mais FJ; Mittendorf J; Schäfer M; Schirok H; Stasch JP; Stoll F; Straub A
Angew Chem Int Ed Engl; 2013 Sep; 52(36):9442-62. PubMed ID: 23963798
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
